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Abstract
Infantile hepatic haemangioma (IHH) is a rare vascular tumour that is potentially lethal due to its associated complications,
including heart failure, hepatic failure, hypothyroidism and abdominal compartment syndrome. The authors report a case
of an asymptomatic diffuse IHH in a newborn male, which was presented as an incidental finding at the time that the
patient was diagnosed with pyloric stenosis. The patient was treated with increasing doses of propranolol that were well
tolerated. With the regression of the IHH by the time that the patient reached one year of age, there was a significant
imagiologic improvement. Because there is no consensus on the optimal approach for the treatment of liver tumours in
newborns, it is important to adopt a systematic approach. After the diagnosis of diffuse IHH has been established, the
decision to initiate treatment and the therapeutic of choice is often controversial. Regular follow-up is recommended to
monitor possible complications.
INTRODUCTION
The incidental finding of a liver tumour in a newborn requires
careful investigation and the exclusion of malignancy. Amongst
other diagnoses, infantile hepatic haemangioma (IHH) should
be included as a possible differential diagnosis. IHH is a rare
vascular tumour, which despite its benign histology, can be
aggressive and potentially lethal [1]. IHH can be classified by
the following three types of lesions: focal, diffuse and multi-
focal [1]. Each lesion type has distinct characteristics that refer
to their prognosis, radiologic features, clinical presentation and
physiologic behaviour [1].
IHH can be asymptomatic, presenting as an incidental
imaging finding, or it can manifest as a complication (e.g. heart
failure, hepatic failure, hypothyroidism or abdominal compart-
ment syndrome) [1–3]. While the treatment options for IHH are
controversial, they can include surgery, propranolol chemo-
therapy, corticosteroids and other immunomodulators. The
authors of the current report discuss a case where a diffuse
IHH was incidentally found in a newborn male. The case’s
therapeutic approach and follow-up management strategy are
also reviewed.
CASE REPORT
On the 24th day of his life, a term newborn male was presented
to the emergency department with non-bilious projectile vomiting
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for 48h. He was born full term via vaginal delivery following a
non-complicated pregnancy and normal prenatal sonograms. The
newborn’s birth weight, birth length and head circumference
were 3050 g, 47 cm and 35.5 cm, respectively. Physical examin-
ation of the newborn proved to be unremarkable, with no indica-
tions of skin lesions or palpable visceral enlargement.
The diagnosis of pyloric stenosis (PS) was established with
an abdominal ultrasound that revealed pyloric muscle thick-
ness (4mm) and pyloric canal length (25mm) that were above
the normal limits. In addition to the PS, the ultrasound revealed
hepatomegaly with a heterogeneous structure due to multiple
hypoechoic nodules that presented in both liver lobes (Fig. 1a
and b). The differential diagnosis included diffuse IHH, hepato-
blastoma and an unknown metastasized primary tumour. Blood
tests were within the normal range, excluding complications or
malignant aetiology. These included blood count, electrolytes,
alpha fetoprotein, vanillylmandelic acid, neuron specific enolase
and liver and thyroid function tests. The imagological study
was complemented by abdominal magnetic resonance. The
craniocaudal dimension of the liver was 78.5mm, and the
abdominal magnetic resonance confirmed countless nodules in
both hepatic lobes. Characteristic of diffuse IHH, these findings
included hyperintense lesions with prominent flow void on T2
imaging and hypointense lesions on T1 imaging (Fig. 2a and b).
An echocardiogram that was performed to exclude complica-
tions revealed no alterations.
The PS was treated with pyloromyotomy, which proved to
be uneventful. After stabilization, the patient’s treatment for
IHH was initiated with propranolol. Doses of propranolol started
at 1mg/kg/day and increased to 3mg/kg/day. Treatment was
well tolerated, and the patient was discharged on the ninth day
of treatment. No adverse effects were registered upon initiation
or during the course of treatment. After 3 weeks of treatment,
an abdominal ultrasound showed numeric and volumetric
regression of the hepatic nodules and reduced heterogeneous
hepatic structure. In addition, a Doppler ultrasound showed
decreased blood flow. During the initial ultrasound, the largest
nodules measured in at 14mm. At the third and eighth weeks,
the largest nodules measured in at 10 and 6mm, respectively.
When the patient reached 15 months of age, a follow-up ultra-
sound revealed a single hepatic nodule that measured in at
6mm. At this time, the patient was still being treated with pro-
pranolol (1.8mg/kg/day).
DISCUSSION
Currently, there is controversy about how IHH should be mana-
ged. There have been a few small case series and some isolated
case reports about IHH but no consensual published guidelines.
Treatment approaches must be decided according to each indi-
vidual, considering each patient’s condition and the number,
location and dimensions of their lesions [1, 4]. Christison-Lagay
et al. proposed a treatment algorithm that considers a conser-
vative approach in patients with asymptomatic focal or multi-
focal lesions through regular follow-up and ultrasonography.
With this algorithm, a complete regression typically occurs
within 2 years of age [1, 4–7]. Since the progression of these
lesions can lead to fatal complications shortly after the onset of
symptoms, pharmacologic or surgical treatment is recom-
mended for diffuse or symptomatic IHH [1]. Complications of
IHH include hepatic failure, massive hepatomegaly that causes
abdominal compartment syndrome, congestive heart failure
Figure 1: Abdominal ultrasound revealing heterogeneous hepatic structure due
to countless hypoechoic nodules (a) with diffuse hypervascularization areas in
Doppler ultrasound (b)
Figure 2: Abdominal magnetic resonance revealing countless nodules in all
hepatic lobes, hyperintense on T2 imaging (a—axial plane; b—coronal plane)
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due to shunting and/or severe hypothyroidism and hypothy-
roidism caused by the overproduction of type III iodothyronine
deiodinase [1–3]. Diffuse IHH patients are at a high risk for mor-
tality and complications [2, 8]. Kulungowski et al. [2] reported a
higher prevalence of heart failure and hypothyroidism in
patients with diffuse IHH than in patients with focal and multi-
focal IHH .
Traditionally, steroids, chemotherapy, radiotherapy and
alpha interferon have been used to pharmacologically treat IHH
[1, 4, 5]. These treatment options have presented serious and
well-known side effects and variable rates of success. Refractory
cases may require surgical management or even a combined
approach of medical and surgical therapy [1, 10]. Due to the
higher risk of complications and death, diffuse IHH patients
may also require hepatic transplantation [1].
Propranolol is a beta blocker that has commonly been used
to treat paediatric patients with cardiac disease, and since
2008, cutaneous infantile haemangiomas [7]. The safety, effi-
cacy and success rate of propranolol in cutaneous infantile
haemangiomas has made it the first line of treatment for this
condition [11]. In more recent publications, propranolol has
been reported to be successful in the treatment of non-
cutaneous haemangiomas, producing no significant adverse
effects under the prescribed doses [9, 12]. While propranolol’s
mechanism of action is partially unknown, its benefits can
include vasoconstriction, apoptosis of the capillary endothelial
cells and decreased expression of the vascular endothelial
growth factor and fibroblast growth factor [9, 12]. Since treat-
ment with steroids can increase the activity of propranolol,
some authors have also suggested an association between pro-
pranolol and prednisone during therapy for diffuse IHH [13, 14].
The approach to this case included a multidisciplinary dis-
cussion with the participation of radiologists, neonatologists
and paediatric surgeons. Upon consideration of the diffuse
nature of IHH, with countless lesions, extensive hepatic
involvement and the associated high risk for complications in
this setting, it was decided that the patient should be treated
with propranolol. The propranolol was well tolerated. Doses
started at 1mg/kg/day and were titrated to a target dose of
3mg/kg/day [9, 11]. Ultrasound re-evaluations at 1, 2, 4, 6 and
12 months of age sufficiently documented the regression of the
hepatic lesions. In summary, the authors found this strategy to
be safe and successful.
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